Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
De Faire Medical
Stockholm, Sweden
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
De Faire Medical has developed AB001, a proprietary probiotic formulation designed to break down alcohol in the gut before it reaches the liver. Clinical results published in the journal Nutrition and Metabolic Insights (2022) indicated that the formulation could reduce blood alcohol levels by up to 70% within 60 minutes of consumption compared to a placebo.
- Therapeutic areas
- OtherGastroenterologyMetabolic Disorders
- Modalities
- Microbial therapyLive biotherapeutic product therapyPeptides
- Industry
- Food & Nutrition
02
Partnerships
Beyond the preview
Go deeper on De Faire Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on De Faire Medical.